Denosumab and Zoledronic Acid Differently Affect Circulating Immune Subsets: A Possible Role in the Onset of MRONJ.

Dmab-Treated Patients Show a Normal Level of Circulating γδ T Cells We monitored γδ T cells due to their reported role in maintaining bone oral cavity homeostasis, observing that, in Dmab-treated patients, circulating γδ T cells remained constant for 12 months, and then an increasing trend was evident at T18. γδ T cell level dramatically decreased at T6 after starting Zol treatment (2.4 ± 1.9 vs. 0.5 ± 0.6, p < 0.05) and remained constantly low during the rest of the observational period ( Figure 4 A).

also in 44,861 other papers